GT Biopharma, Inc.
Balance Sheet
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $6.8M | $4.0M | $1.1M | $5.7M | $9.0M | $5.3M | $28.0K | $60.0K |
| Accounts Receivable | — | — | — | — | — | — | — | — |
| Inventory | — | — | — | — | — | — | — | — |
| Total Current Assets | $8.1M | $4.2M | $14.1M | $16.6M | $32.2M | $5.7M | $274.0K | $90.0K |
| Property, Plant & Equipment | — | — | — | — | — | — | $0 | $35.0K |
| Goodwill | — | — | — | — | — | — | — | — |
| Intangible Assets (Excl. Goodwill) | — | — | — | — | — | — | — | — |
| Total Assets | $8.1M | $4.2M | $14.1M | $16.7M | $32.2M | $5.7M | $396.0K | $25.4M |
| Liabilities | ||||||||
| Accounts Payable | $748.0K | $3.9M | $4.3M | $3.1M | $8.2M | $2.2M | $1.9M | $1.8M |
| Total Current Liabilities | $2.3M | $5.9M | $6.6M | $4.9M | $10.3M | $35.1M | $19.7M | $14.0M |
| Long-Term Debt | — | — | — | — | — | — | — | — |
| Total Liabilities | $1.3M | $5.9M | $6.6M | $5.0M | $10.3M | $35.1M | $19.7M | $14.0M |
| Stockholders' Equity | ||||||||
| Retained Earnings | $-723.9M | $-695.2M | $-682.1M | $-674.5M | $-653.6M | $-595.8M | $-567.3M | $-528.7M |
| Total Stockholders' Equity | $5.8M | $-1.7M | $7.5M | $11.7M | $21.9M | $-29.4M | $-19.3M | $11.4M |